Sign in

    David Carter

    Senior Equity Analyst and Managing Director at RBC Capital Markets

    David Carter is a Senior Equity Analyst and Managing Director at RBC Capital Markets, specializing in healthcare and biotechnology sector research with a particular focus on major companies such as Amgen, Biogen, and Regeneron. He is recognized for his detailed coverage and has consistently delivered strong performance in analyst rankings, boasting high success rates and above-market returns as measured by independent platforms. Carter began his career in equity research in the early 2000s, holding previous roles at leading investment banks prior to joining RBC Capital Markets in 2013. He maintains professional credentials including FINRA Series 7, 63, and 86/87 licenses, underscoring his expertise and regulatory compliance in securities analysis.

    David Carter's questions to BIO-RAD LABORATORIES (BIO) leadership

    David Carter's questions to BIO-RAD LABORATORIES (BIO) leadership • Q2 2025

    Question

    David Carter, on for Connor McNamara at RBC, asked for confirmation of the implied organic growth ramp in the second half of the year and questioned the initial customer response to the new Continuum ddPCR platform, particularly from lower-throughput labs.

    Answer

    Executive VP & CFO Roop Lakkaraju confirmed the implied organic growth progression for the second half was accurate. President & COO Jonathan DiVincenzo explained that the Q4 ramp is partly due to an easier comparison from the prior year when China's reimbursement changes first hit. Regarding the Continuum platform, DiVincenzo stated it is still too early for direct user feedback but highlighted its flexibility for both single-sample and 96-well plate runs is a key advantage being promoted to customers.

    Ask Fintool Equity Research AI